Milestone Pharmaceuticals Presents Data from Analysis of Etripamil Nasal Spray in Patients Experiencing Atrial Fibrillation with Rapid Ventricular Rate
Portfolio Pulse from Benzinga Newsdesk
Milestone Pharmaceuticals (NASDAQ:MIST) announced promising data from an ad hoc analysis of a subset of patients experiencing atrial fibrillation with rapid ventricular rate (AFib-RVR) in the NODE-303 study, which evaluated etripamil, the Company's investigational calcium channel blocker.
May 22, 2023 | 11:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Milestone Pharmaceuticals' promising data from the NODE-303 study on etripamil may positively impact the company's stock price.
The promising data from the NODE-303 study on etripamil, Milestone Pharmaceuticals' investigational calcium channel blocker, indicates potential success in the development and commercialization of the drug. This positive news may lead to increased investor confidence and a potential rise in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100